secwatch.observer — SEC 8-K summary
======================================

Issuer:     Stoke Therapeutics, Inc. (STOK)
CIK:        0001623526
Form:       8-K
Filed at:   2023-09-20T23:59:59+00:00
Accession:  0001193125-23-238627
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stoke Therapeutics appoints Ian Smith to Board of Directors
-----------------------------------------------------------

- Ian Smith appointed as Class II director effective September 19, 2023.
- He will receive an annual cash retainer of $40,000 and an initial stock option for 96,340 shares (~$305k fair value).
- Smith brings over 20 years experience; served as EVP/COO/CFO at Vertex Pharmaceuticals.
- He currently serves on boards of Solid Biosciences (SLDB), Foghorn Therapeutics (FHTX), and others.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1623526/000119312523238627/0001193125-23-238627-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1623526/000119312523238627/d516489d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-238627

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer